Recursion Pharmaceuticals Net Worth
Recursion Pharmaceuticals Net Worth Breakdown | RXRX |
Recursion Pharmaceuticals Net Worth Analysis
Recursion Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Recursion Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Recursion Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Recursion Pharmaceuticals' net worth analysis. One common approach is to calculate Recursion Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Recursion Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Recursion Pharmaceuticals' net worth. This approach calculates the present value of Recursion Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Recursion Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Recursion Pharmaceuticals' net worth. This involves comparing Recursion Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Recursion Pharmaceuticals' net worth relative to its peers.
To determine if Recursion Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Recursion Pharmaceuticals' net worth research are outlined below:
Recursion Pharmaceuticals had very high historical volatility over the last 90 days | |
The company reported the previous year's revenue of 58.84 M. Net Loss for the year was (463.66 M) with loss before overhead, payroll, taxes, and interest of (372.61 M). | |
Recursion Pharmaceuticals currently holds about 515.44 M in cash with (359.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.98. | |
Recursion Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
Roughly 69.0% of the company shares are owned by institutional investors |
Recursion Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Recursion Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Recursion Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
26th of February 2024 Upcoming Quarterly Report | View | |
13th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
26th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Follow Recursion Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.81 B.Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Recursion Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Recursion Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Recursion Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Recursion Pharmaceuticals time-series forecasting models is one of many Recursion Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Recursion Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Recursion Pharmaceuticals Earnings per Share Projection vs Actual
Recursion Pharmaceuticals Corporate Management
Najat Khan | Chief Officer | Profile | |
Christopher Gibson | CEO CoFounder | Profile | |
Kevin Leggat | Vice Accounting | Profile | |
Janelle Gordon | Vice Operations | Profile | |
Shafique MD | Interim Officer | Profile | |
Lina Nilsson | Senior Platform | Profile |
Additional Tools for Recursion Stock Analysis
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.